# Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

> **NCT00932646** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 100 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BI 1744 (Olodaterol) Low Dose
- **DRUG:** BI 1744 (Olodaterol) Medium Dose
- **DRUG:** Placebo
- **DRUG:** Foradil

## Key facts

- **NCT ID:** NCT00932646
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-05
- **Final completion:** —
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932646, "Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00932646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*